What question did this study set out to answer?

To evaluate the safety, tolerability, and clinical performance of subcutaneous implantable cardioverter-defibrillator (S-ICD) systems over a 6-month follow-up period.

September 8, 2022Rational Pharmacotherapy in CardiologyOpen Access

Safety and Tolerability of Implanted Subcutaneous Cardioverter-Defibrillator Systems

View Full Paper

Ask AI

Bookmark

Why the study?

The study aimed to assess the safety and tolerability of the subcutaneous implantable cardioverter defibrillator (S-ICD) after implantation.

Is subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation safe and tolerable in patients requiring sudden cardiac death prevention without need for pacing?

Population

33 patients with indications for primary or secondary prevention of sudden cardiac death

Comparison

Subcutaneous implantable cardioverter defibrillator (S-ICD) implantation

Design

Observational study

Follow-up

6 months

Authors

АВА В ВерещагинаWeatherford College TUT. M. UskachRussian Medical Academy of Continuous Professional Education OSO. V. SapelnikovNational Medical Research Center of Cardiology

Discussion

Member takes

Implication

Supports short-term S-ICD safety in selected patients; hypothesis-generating and requires randomized confirmation.

Key Points

To evaluate the safety, tolerability, and clinical performance of subcutaneous implantable cardioverter-defibrillator (S-ICD) systems over a 6-month follow-up period.
Observational study evaluating N=33 patients (84% male, median age 57 years, median LVEF 30%) receiving an S-ICD for primary (97%) or secondary prevention of sudden cardiac death.
Excluded patients requiring antibradycardia or resynchronization therapy, those with sustained monomorphic ventricular tachycardia, or QRS duration >130 ms.
Conducted pre-implantation examinations, intraoperative defibrillation testing, two-zone device programming, and a 6-month follow-up evaluating device interrogations, shock episodes, and quality of life.
Device sensing setup utilized the primary vector in 63.6%, secondary vector in 27.2%, and alternative vector in 9.2% of patients under two-zone programming (mean shock zone 222 beats/min).
Perioperative complications occurred in 2 patients, with no shocks recorded in 27 patients and adequate shocks delivered in 2 patients over 6 months.
No cardiovascular rehospitalizations occurred, with 1 non-cardiovascular death reported due to viral pneumonia complications.

Structured PICO

Is subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation safe and tolerable in patients requiring sudden cardiac death prevention without need for pacing?

Population

33 patients >18 years old with indications for primary or secondary prevention of sudden cardiac death, mean age 57, 84% male. Excluded: indications for transvenous ICD (sustained monomorphic VT, need for anti-bradycardia or resynchronization therapy) and QRS > 130 msec.

Intervention

Subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation

Outcome

Safety and tolerability (episodes of shock therapy, complications, quality of life) at 6 months follow-upsafety

S-ICD implantation is safe, tolerable, and effective for preventing sudden cardiac death in appropriately selected patients without a need for antibradycardia pacing.

Cite This Study

Верещагина et al. (2022) studied this question.

synapsesocial.com/papers/6a1992503f3ec013f0dec46c https://doi.org/10.20996/1819-6446-2022-08-05

Topics

Cardiac device therapy

View Full Paper

Ask AI

Bookmark

Safety and Tolerability of Implanted Subcutaneous Cardioverter-Defibrillator Systems

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Safety and Tolerability of Implanted Subcutaneous Cardioverter-Defibrillator Systems

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider